Results Presented at International Society of Hematology Meeting July 5-9 2002, Quebec
VANCOUVER, July 9 /PRNewswire-FirstCall/ - AnorMED Inc. (TSE: AOM - News) announced today that new clinical results from a Phase I study in eighteen healthy volunteers support the use of AMD-3100 as a potential new agent in stem cell transplant. Stem cell transplant is used to restore the immune system of patients who have been treated for cancers involving the blood and immune system such as leukemias, multiple myeloma and lymphomas.

"We are very encouraged by data coming out of our AMD-3100 clinical program and continue to believe AMD-3100 may improve the overall stem cell transplantation procedure and potentially enhance patient outcome," said Dr. Gary Calandra, MD, PhD, VP Clinical Development at AnorMED Inc.

Transplantation involves the collection of certain types of stem cells, specifically CD34+ cells. These cells are then re-administered to the patient after the cancer treatment.

"In stem cell transplant it is very important to be able to collect as many stem cells as possible from the patient prior to their cancer treatment. This can greatly improve the chances that their immune system can be restored. Our new data show that the combined use of AMD-3100 and a standard agent used in stem cell transplant for cancer patients, called Neupogen, act synergistically generating more stem cells than either agent alone," added Dr. Calandra.

Study results presented today at the International Society of Hematology meeting confirm that the increase in stem cells induced by AMD-3100, given as a single subcutaneous injection, is dose-dependent and that AMD-3100 enhances the effect of Neupogen. In addition, results from a second study also presented at the conference confirm that stem cells mobilized by AMD-3100 alone in healthy volunteers can successfully re-establish a damaged immune system and function normally in preclinical models. To date, AMD-3100 has been generally well tolerated in all volunteer studies. Abstracts are available at
AnorMED plans to initiate a third Phase I trial in a small number of cancer patients to confirm that AMD-3100 alone increases stem cells in this patient population. Based on the positive data from this study, the Company hopes to initiate a Phase II trial of stem cell transplantation in cancer patients using AMD-3100 in combination with Neupogen before year end.

AnorMED's core strength involves the application of chemistry, biochemistry and biology to the discovery and development of small molecule therapeutics for the treatment of diseases including HIV inflammation and cancer.

The Company's clinical products include: Fosrenol, exclusively licensed to Shire Pharmaceuticals Group plc, which is on track for a European market approval by mid-year 2002; AMD-473, a new platinum based anti-cancer agent, in ongoing Phase II trials; AMD-3100, a potential new agent for stem cell transplant in cancer patients currently in a Phase I trial; and Apomate, a prognostic imaging agent for cancer and other diseases, which employs a technology licensed to North American Scientific Inc. The Company is also focused on a novel class of compounds that target specific receptors known to be involved in HIV, rheumatoid arthritis, asthma and cancer. AnorMED continues to build upon its drug discovery and clinical development capabilities to support the rapid advancement of its most promising therapeutic candidates into clinical trials and to attract corporate partners.

Note: Certain of the statements contained in this press release contain forward-looking statements which involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. The Company does not expect to update forward-looking statements continually as conditions change. Investors are referred to the full discussion of risk factors associated with the Company's business contained in the Company's Annual Information Form filed with securities regulatory authorities dated August 17, 2001.

For further information:
Elisabeth Whiting, M.Sc. .
Director, Investor Relations
Tel: (604) 532-4667
Notes to Editors and Reporters:

Background on Stem Cell Transplant

Approximately 50,000 stem cell transplantations are performed yearly worldwide. Stem cells used to be collected from patients using an invasive procedure called bone marrow transplant. This technique is now being replaced by a new procedure called peripheral blood stem cell transplant (PBSCT). In this procedure, stem cells are collected from the circulating blood for transplantation. Prior to collection patients are given a growth factor called Neupogen (G-CSF -granulocyte colony stimulating factor) which causes stems cells in the body to multiply. The objective of this procedure is to get as many stems cells as possible into the circulating blood where they can be collected. However, many stem cells remain locked up in the bone marrow. AMD- 3100 has been shown to mobilize stem cells, causing them to move out of the bone marrow and into the circulating blood. When used in combination, AMD-3100 and Neupogen work together to generate an increase in the number of circulating stem cells. In this capacity, AMD-3100 may enhance the stem cells available for collection as well as improve the transplantation procedure by reducing the number of times cells would have to be collected.

Background on AMD-3100

AMD-3100 is an inhibitor of the CXCR4 chemokine receptor. The CXCR4 receptor is present on white blood cells and, among other functions, has been shown to play a key regulatory role in the trafficking and homing of human CD34+ stem cells in the bone marrow.